AstraZeneca Faces Class Action Lawsuits Over China Legal Issues
AstraZeneca plc (AZ, NASDAQ: AZN) is facing multiple class action lawsuits in the United States...
Finance
Weimai Qingtong Medical Technology Completes Tens of Millions Yuan B+ Round
Weimai Qingtong Medical Technology (WEMT), a medical device company based in Wuxi, has completed a...
Stedical Scientific Raises RMB100M in Series B Financing for Global Expansion
Stedical Scientific, a Hangzhou-based tissue engineering and regenerative medicine company, has raised over RMB100 million...
Yantai Dongcheng’s Lannacheng Bio Secures RMB150m to Advance [18F] Spiritide Study
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675)’s controlling subsidiary, Yantai Lannacheng Biotechnology Co., Ltd.,...
Beijing Wanjie Medical Device Completes Near-Hundred Million Yuan B-Round Financing
Beijing Wanjie Medical Device Co., Ltd. recently announced the successful completion of a B-round financing...
LinkZill Completes Multi-Million-Dollar A-Round Financing Led by ProximaVentures
Hangzhou LinkZill Technology Co., Ltd. has recently completed a multi-million-dollar A-round financing, exclusively led by...
Nanos Medical Raises Over RMB300m to Boost Otolaryngology Device Lead
China-based Nanos Medical (Shanghai) Limited, an otolaryngology device maker, has reportedly raised over RMB300 million...
StairMed Raises Record RMB350m for Implantable BCI Development
Shanghai StairMed Technology Co., Ltd., a specialist in implantable brain-computer interface (BCI) technology, has reportedly...
Anhui Anke to Invest in Visen Pharma’s Hong Kong IPO as Cornerstone Investor
China – based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) has announced its plan...
Novartis to Acquire Anthos Therapeutics for $3.1B, Boosting Factor XI Inhibitor Portfolio
Swiss pharma giant Novartis (NYSE: NVS) announced plans to acquire Anthos Therapeutics, Inc., a cardiometabolic-focused...
R-Nanoablation Raises USD 13.7M in Series B+ to Advance Nanosecond Ablation Tech
Hangzhou-based R-Nanoablation, a minimally invasive medical device developer, has raised over RMB 100 million (USD...
Xtalpi Invests in Alternative Bio for Cancer and Inflammation Drugs
Shenzhen-based QuantumPharm Inc. (HKG: 2228), also known as Xtalpi Inc., announced a strategic investment in...
CR Sanjiu Gains SASAC Approval for Tasly Pharma Acquisition
China-based CR Sanjiu (SHE: 000999), a state-owned pharmaceutical company, has received approval from the State-owned...
Regeneron’s Q4 Financials Show 10% Revenue Growth, Driven by Eylea and Libtayo
US-based biopharmaceutical company Regeneron (NASDAQ: REGN) released its Q4 2024 financial report, showing revenues up...
Tofflon to Join Shanghai Biomedical M&A Fund with Leading Firms
China-based Tofflon Science and Technology Group Co., Ltd. (SHE: 300171), a total solution service provider...
PegBio’s Lead Product PB-119 Clears HKEX Hearing for Type 2 Diabetes and Obesity Treatment
On January 28, 2025, the Hong Kong Stock Exchange (HKEX) website showed that PegBio Co.,...
Vigonvita Life Sciences Targets HKEX IPO with Integrated Biopharma Model
On January 27, 2025, the Hong Kong Stock Exchange (HKEX) website displayed that Suzhou Vigonvita...
Jiangsu Yuyue Partners with Inogen for International Distribution and R&D
China-based Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (SHE: 002223) has struck a partnership...
Jiangsu Vcare PharmaTech Secures RMB200 Million in Series C+ Financing
Jiangsu Vcare PharmaTech Co., Ltd., a China – based high – tech pharmaceutical company, has...
ConjuStar Raises RMB100 Million to Advance X-Drug Conjugates Pipeline
ConjuStar, a specialist in X-Drug conjugates (XDCs) based in Tianjin, has reportedly raised RMB100 million...